Jazz Pharmaceuticals plc
JAZZ
$103.58
$5.805.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.76% | 6.12% | 5.23% | 3.91% | 2.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.76% | 6.12% | 5.23% | 3.91% | 2.81% |
| Cost of Revenue | 13.50% | 10.56% | -0.57% | -10.86% | -19.40% |
| Gross Profit | 5.01% | 5.69% | 5.84% | 5.65% | 5.64% |
| SG&A Expenses | 15.95% | 8.31% | 8.48% | 1.32% | 0.05% |
| Depreciation & Amortization | 1.92% | 3.13% | 4.35% | 6.36% | 6.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.21% | 6.28% | 6.09% | 6.51% | 6.67% |
| Operating Income | -1.12% | 5.49% | 1.93% | -6.37% | -12.26% |
| Income Before Tax | 51.88% | 58.92% | 470.92% | 209.82% | 171.91% |
| Income Tax Expenses | -30.12% | 23.75% | 64.36% | 45.68% | 46.75% |
| Earnings from Continuing Operations | 45.77% | 35.02% | 479.28% | 556.49% | 311.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.77% | 35.02% | 479.28% | 556.49% | 311.66% |
| EBIT | -1.12% | 5.49% | 1.93% | -6.37% | -12.26% |
| EBITDA | 0.71% | 4.50% | 2.96% | -0.78% | -4.09% |
| EPS Basic | 49.57% | 38.88% | 504.09% | 546.70% | 310.66% |
| Normalized Basic EPS | 12.81% | 19.44% | 14.99% | 1.04% | -15.38% |
| EPS Diluted | 54.76% | 43.64% | 710.31% | 468.70% | 290.43% |
| Normalized Diluted EPS | 19.26% | 30.17% | 16.42% | -2.81% | -20.95% |
| Average Basic Shares Outstanding | -2.54% | -2.29% | -1.67% | -0.87% | 0.18% |
| Average Diluted Shares Outstanding | -7.86% | -10.91% | -5.91% | -0.01% | 5.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |